CY1114815T1 - Χορηγηση θεραπευτικων χημικων ενωσεων στον εγκεφαλο και σε αλλους ιστους - Google Patents
Χορηγηση θεραπευτικων χημικων ενωσεων στον εγκεφαλο και σε αλλους ιστουςInfo
- Publication number
- CY1114815T1 CY1114815T1 CY20141100019T CY141100019T CY1114815T1 CY 1114815 T1 CY1114815 T1 CY 1114815T1 CY 20141100019 T CY20141100019 T CY 20141100019T CY 141100019 T CY141100019 T CY 141100019T CY 1114815 T1 CY1114815 T1 CY 1114815T1
- Authority
- CY
- Cyprus
- Prior art keywords
- administration
- mps
- brain
- tissue
- iduronidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με την ενδορραχιαία χορήγηση (IT) του ανασυνδυασμένου ενζύμου για την θεραπεία των διαταραχών της λυσοσωματικής αποθήκευσης. Σε μία παραδειγματική εφαρμογή, η ενδορραχιαία χορήγηση των ενέσεων της ανθρώπινης α-Λ-ιδουρονιδάσης (rhIDU) σε μολυσμένα ζώα με MPS I είχε ως αποτέλεσμα την σημαντική πρόσληψη του ενζύμου, την σημαντική δραστικότητα της rh-ιδουρονιδάσης στον εγκέφαλο και τους μήνιγγες και μία μείωση στην αποθήκευση της γλυκοσαμινογλυκάνης (GAG) στα κύτταρα των υποκειμένων με MPS I σε σχέση με αυτή των φυσιολογικών υποκειμένων. Η ενδορραχιαία χορήγηση αποδείχθηκε περισσότερο αποτελεσματική από την ενδοφλέβια θεραπεία ως προς την ανακούφιση των συμπτωμάτων της MPS I, καταδεικνύοντας την ως μία χρήσιμη μέθοδο για την θεραπεία των διαταραχών στην λυσοσωματική αποθήκευση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/651,493 US7442372B2 (en) | 2003-08-29 | 2003-08-29 | Delivery of therapeutic compounds to the brain and other tissues |
EP04782579.9A EP1673104B2 (en) | 2003-08-29 | 2004-08-30 | Delivery of therapeutic compounds to the brain and other tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114815T1 true CY1114815T1 (el) | 2016-12-14 |
Family
ID=34217412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100019T CY1114815T1 (el) | 2003-08-29 | 2014-01-09 | Χορηγηση θεραπευτικων χημικων ενωσεων στον εγκεφαλο και σε αλλους ιστους |
Country Status (12)
Country | Link |
---|---|
US (5) | US7442372B2 (el) |
EP (1) | EP1673104B2 (el) |
JP (1) | JP5819574B2 (el) |
AU (1) | AU2004268645B2 (el) |
CA (1) | CA2537238C (el) |
CY (1) | CY1114815T1 (el) |
DK (1) | DK1673104T4 (el) |
ES (1) | ES2441612T5 (el) |
PL (1) | PL1673104T5 (el) |
PT (1) | PT1673104E (el) |
SI (1) | SI1673104T2 (el) |
WO (1) | WO2005021064A2 (el) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6585971B1 (en) * | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
JP2008503590A (ja) * | 2004-06-21 | 2008-02-07 | メドトロニック・インコーポレーテッド | 組成物を細胞にデリバリーするための医学用システム及び方法 |
AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
EP1988823B1 (en) * | 2006-02-09 | 2018-08-15 | Genzyme Corporation | Slow intraventricular delivery |
EP2046435A4 (en) * | 2006-07-13 | 2012-06-27 | Medtronic Inc | METHOD AND FORMULATIONS FOR OPTIMAL LOCAL ADMINISTRATION OF CELL THERAPY BY MEANS OF MINIMALLY INVASIVE PROCEDURES |
US8849372B2 (en) * | 2006-11-22 | 2014-09-30 | The General Hospital Corporation | Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent |
US20080140008A1 (en) * | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Intrathecal catheter |
DK2121713T3 (da) | 2007-01-18 | 2013-06-24 | Genzyme Corp | Oligosaccharider, omfattende en aminooxygruppe, og konjugater deraf |
WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
ES2635726T3 (es) * | 2007-06-06 | 2017-10-04 | Genzyme Corporation | Terapia génica para enfermedades de almacenamiento lisosómico |
US8366652B2 (en) | 2007-08-17 | 2013-02-05 | The Invention Science Fund I, Llc | Systems, devices, and methods including infection-fighting and monitoring shunts |
US8702640B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | System, devices, and methods including catheters configured to monitor and inhibit biofilm formation |
US8029740B2 (en) | 2008-07-11 | 2011-10-04 | The Invention Science Fund I, Llc | Event-triggered self-sterilization of article surfaces |
US8753304B2 (en) | 2007-08-17 | 2014-06-17 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter |
US8734718B2 (en) | 2007-08-17 | 2014-05-27 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component |
US8460229B2 (en) | 2007-08-17 | 2013-06-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states |
US8162924B2 (en) | 2007-08-17 | 2012-04-24 | The Invention Science Fund I, Llc | System, devices, and methods including actively-controllable superoxide water generating systems |
US8114346B2 (en) * | 2007-08-17 | 2012-02-14 | The Invention Science Fund I, Llc | Event-triggered ultraviolet light sterilization of surfaces |
US8706211B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having self-cleaning surfaces |
US20090048648A1 (en) * | 2007-08-17 | 2009-02-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Self-sterilizing device |
US8647292B2 (en) | 2007-08-17 | 2014-02-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states |
US9005263B2 (en) | 2007-08-17 | 2015-04-14 | The Invention Science Fund I, Llc | System, devices, and methods including actively-controllable sterilizing excitation delivery implants |
US8742079B2 (en) * | 2007-08-20 | 2014-06-03 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
EP2219666A4 (en) * | 2007-11-15 | 2011-05-25 | Univ North Carolina | PROSTATE ACID PHOSPHATASE FOR THE TREATMENT OF PAIN |
PL2279210T3 (pl) | 2008-05-07 | 2017-10-31 | Biomarin Pharm Inc | Lizosomalne peptydy kierujące i ich zastosowania |
US20120041286A1 (en) | 2008-12-04 | 2012-02-16 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems, devices, and methods including implantable devices with anti-microbial properties |
US8585627B2 (en) | 2008-12-04 | 2013-11-19 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure |
EP2889043B1 (en) | 2008-12-16 | 2019-04-10 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
EP3075386B1 (en) | 2009-06-17 | 2019-10-16 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
EP3482767B1 (en) * | 2009-08-28 | 2021-10-06 | Icahn School of Medicine at Mount Sinai | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
RU2012154576A (ru) * | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки к цнс гепаран-n-сульфатазы |
RU2660348C2 (ru) * | 2010-06-25 | 2018-07-05 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки в цнс идуронат-2-сульфатазы |
EP2588130B1 (en) * | 2010-06-25 | 2016-08-17 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
JP6063380B2 (ja) * | 2010-06-25 | 2017-01-18 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | サンフィリポ症候群b型の処置 |
NZ702800A (en) * | 2010-06-25 | 2017-03-31 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of heparan n-sulfatase |
IL291556B2 (en) * | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Methods and compositions for administration of arylsulfatase A to the central nervous system |
EP2588132A4 (en) * | 2010-06-25 | 2014-10-15 | Shire Human Genetic Therapies | METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS |
JP2012062312A (ja) * | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
DK2665814T3 (en) | 2011-01-20 | 2017-09-11 | Protalix Ltd | NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS |
AU2012322811A1 (en) * | 2011-10-12 | 2014-05-01 | Synageva Biopharma Corp. | Recombinant human NaGlu protein and uses thereof |
US9101678B2 (en) | 2011-11-03 | 2015-08-11 | Elwha Llc | Heat-sanitization of surfaces |
EP2776553B1 (en) * | 2011-11-07 | 2018-07-11 | Shire Human Genetic Therapies, Inc. | Biomarkers for sanfilippo syndrome and uses thereof |
EP2785378B1 (en) * | 2011-12-02 | 2020-05-13 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
AU2012358223B2 (en) * | 2011-12-23 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
EP2880156B1 (en) * | 2012-07-31 | 2017-08-23 | biOasis Technologies Inc | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
AU2013296170A1 (en) | 2012-08-03 | 2015-03-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Cyclodextrin for the treatment of lysosomal storage diseases |
KR102262882B1 (ko) | 2012-11-27 | 2021-06-10 | 바이오마린 파머수티컬 인크. | 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 |
EA201590582A1 (ru) * | 2012-12-07 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для лечения мукополисахаридоза типа iiia с использованием интратекального введения |
AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
CN115120746A (zh) * | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
US9994641B2 (en) | 2013-12-25 | 2018-06-12 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody that passes through blood-brain barrier |
TWI752907B (zh) | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
BR112017026287A2 (pt) | 2015-06-10 | 2018-09-18 | Vtesse Inc | composições de hidroxipropil beta-ciclodextrina e métodos |
CN114409783A (zh) | 2015-06-24 | 2022-04-29 | Jcr制药股份有限公司 | 通过血脑屏障的抗人转铁蛋白受体抗体 |
CN107849150B (zh) | 2015-06-24 | 2021-12-14 | Jcr制药股份有限公司 | 含有bdnf的融合蛋白 |
CA3003750A1 (en) | 2015-11-06 | 2017-05-11 | Biomarin Pharmaceutical Inc. | Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes |
AU2017222620B2 (en) | 2016-02-24 | 2022-06-16 | Biomarin Pharmaceutical Inc. | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof |
JP7171439B2 (ja) | 2016-04-15 | 2022-11-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症ii型を処置するための遺伝子療法 |
MX2018014868A (es) * | 2016-06-02 | 2019-09-13 | Cloudbreak Therapeutics Llc | Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma. |
JP2019517274A (ja) | 2016-06-13 | 2019-06-24 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill | 最適化されたcln1遺伝子および発現カセットおよびそれらの使用 |
US20200384061A1 (en) | 2016-12-26 | 2020-12-10 | Jcr Pharmaceuticals Co., Ltd. | Fusion Protein Including BDNF |
AR110586A1 (es) | 2016-12-26 | 2019-04-10 | Japan Chem Res | Anticuerpo de receptor antitransferrina humana que penetra la barrera hematoencefálica |
US11541005B2 (en) | 2017-02-08 | 2023-01-03 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
US11723865B2 (en) | 2017-02-08 | 2023-08-15 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
US11819539B2 (en) | 2017-09-22 | 2023-11-21 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating Mucopolysaccharidosis type II |
MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
US11730767B2 (en) | 2018-02-23 | 2023-08-22 | Regeneration Biomedical, Inc. | Methods, apparatuses and systems for instilling stem cells and pharmaceuticals into the human ventricular system |
CN111587289B (zh) * | 2018-12-18 | 2024-04-12 | 纽卫制药有限公司 | 一种新型药品递送系统及其提供方法 |
EP3670652A1 (en) * | 2018-12-18 | 2020-06-24 | NEUWAY Pharma GmbH | Vlp for the treatment of a lysosomal storage disease |
CN113301925A (zh) | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
US11446084B2 (en) | 2019-07-12 | 2022-09-20 | Neuralink Corp. | Laser drilling of pia mater |
JP2022546042A (ja) | 2019-08-29 | 2022-11-02 | バイオマリン ファーマシューティカル インコーポレイテッド | 小児対象のcln2疾患を治療するための方法 |
CA3164707A1 (en) | 2020-02-03 | 2021-08-12 | Ana Maria Garcia Collazo | Combination therapy for treating mps1 |
CA3207482A1 (en) * | 2021-02-09 | 2022-08-18 | Jill Wood | Nootropic peptides for treating lysosomal storage diseases |
US11958917B2 (en) | 2022-02-18 | 2024-04-16 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2601215A (en) | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
US3505329A (en) | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
JPS5883691A (ja) | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | 1′,2′−ジアシル−(6r,s)−5,6,7,8−テトラヒドロ−l−ビオプテリンおよびその製法 |
JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
CH651755A5 (en) | 1982-03-03 | 1985-10-15 | Kanegafuchi Chemical Ind | Use of pterin derivatives |
GB8318833D0 (en) | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
ZA836957B (en) | 1982-09-20 | 1985-04-24 | Wellcome Found | Neurologically active chemical compounds |
US5196533A (en) | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
US4587340A (en) | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
JPS60178887A (ja) | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−ビオプテリンの製造法 |
JPS60199889A (ja) | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−エリスロ−ビオプテリンの硫酸塩およびその製法 |
US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
DE3437944A1 (de) | 1984-10-17 | 1986-07-31 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt |
US4713454A (en) | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
EP0318926B1 (en) | 1987-11-30 | 1995-05-03 | Kabushiki Kaisha Vitamin Kenkyusyo | Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives |
US6149909A (en) | 1995-06-23 | 2000-11-21 | Women's And Children's Hospital | Synthetic α-L-iduronidase and genetic sequences encoding same |
JP2534423B2 (ja) | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤 |
US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
DE4308739C1 (de) | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
US5945452A (en) | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
ES2177654T3 (es) | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
EP0865499B1 (en) | 1995-09-14 | 2009-03-18 | Virginia Tech Intellectual Properties, Inc. | Production of lysosomal enzymes in plant-based expression systems |
CA2205710A1 (en) | 1996-05-20 | 1997-11-20 | The University Of British Columbia | Murine model for generalized lysosomal storage disorder and methods of making and using same |
US20020076782A1 (en) | 1996-07-05 | 2002-06-20 | John P.N. Rosazza | Purified nitric oxide synthase |
GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
US6458574B1 (en) † | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US5922713A (en) | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
JP4306825B2 (ja) | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
CA2328518A1 (en) * | 1998-05-13 | 1999-11-18 | Harbor-Ucla | Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
US6200758B1 (en) | 1999-02-19 | 2001-03-13 | New York State Office Of Mental Health | Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders |
US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
AU4013900A (en) | 1999-03-19 | 2000-10-09 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
US6585971B1 (en) | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
US6569661B1 (en) | 1999-11-12 | 2003-05-27 | Biomarin Pharmaceutical Inc. | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
EP1227828A1 (en) * | 1999-11-12 | 2002-08-07 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
WO2001036603A2 (en) | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
US6972124B2 (en) * | 2000-05-01 | 2005-12-06 | Biomarin Pharmaceuticals Inc. | Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
US20020006400A1 (en) | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
US6544994B2 (en) | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
AU2001269923A1 (en) * | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
PT3108895T (pt) | 2000-07-18 | 2018-12-18 | Univ Duke | Tratamento de doenças de armazenanto de glicogénio tipo ii |
US20050119270A1 (en) | 2000-08-04 | 2005-06-02 | Mason R. P. | Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release |
BR0113411A (pt) | 2000-08-31 | 2004-01-06 | Daiichi Suntory Pharma Co Ltd | Processo para a produção do composto de biopterina |
JP4641705B2 (ja) * | 2001-04-30 | 2011-03-02 | ザイストール セラピューティクス, インコーポレイテッド | 治療的タンパク質の亜細胞標的化 |
WO2002098455A2 (en) † | 2001-06-07 | 2002-12-12 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
US20030007961A1 (en) | 2001-06-22 | 2003-01-09 | Wilburn Michael D. | Orthomolecular vitamin E derivatives |
US20030072761A1 (en) † | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
US7658916B2 (en) | 2002-04-05 | 2010-02-09 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
US20030198620A1 (en) | 2002-04-16 | 2003-10-23 | Keiya Ozawa | Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions |
EP1503788B1 (en) | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
DE10260263A1 (de) | 2002-12-20 | 2004-07-15 | Biocrates Life Sciences Gmbh | Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen |
EP1613264A4 (en) | 2003-04-16 | 2007-08-15 | Yeda Res & Dev | MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT |
WO2005002515A2 (en) | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
BRPI0517088A (pt) | 2004-11-17 | 2008-09-30 | Biomarin Pharm Inc | formulação de comprimido estável |
-
2003
- 2003-08-29 US US10/651,493 patent/US7442372B2/en active Active
-
2004
- 2004-08-30 EP EP04782579.9A patent/EP1673104B2/en active Active
- 2004-08-30 WO PCT/US2004/028135 patent/WO2005021064A2/en active Application Filing
- 2004-08-30 CA CA2537238A patent/CA2537238C/en active Active
- 2004-08-30 PT PT47825799T patent/PT1673104E/pt unknown
- 2004-08-30 AU AU2004268645A patent/AU2004268645B2/en active Active
- 2004-08-30 PL PL04782579.9T patent/PL1673104T5/pl unknown
- 2004-08-30 DK DK04782579.9T patent/DK1673104T4/da active
- 2004-08-30 US US11/630,446 patent/US9044473B2/en active Active
- 2004-08-30 SI SI200432119T patent/SI1673104T2/sl unknown
- 2004-08-30 ES ES04782579T patent/ES2441612T5/es active Active
- 2004-08-30 JP JP2006524936A patent/JP5819574B2/ja active Active
-
2012
- 2012-02-17 US US13/399,787 patent/US9089566B2/en not_active Expired - Lifetime
-
2014
- 2014-01-09 CY CY20141100019T patent/CY1114815T1/el unknown
-
2015
- 2015-02-05 US US14/615,098 patent/US9572870B2/en not_active Expired - Lifetime
-
2017
- 2017-01-06 US US15/400,289 patent/US11040088B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20170182134A1 (en) | 2017-06-29 |
ES2441612T3 (es) | 2014-02-05 |
DK1673104T4 (da) | 2022-01-17 |
US9572870B2 (en) | 2017-02-21 |
DK1673104T3 (da) | 2014-01-20 |
CA2537238A1 (en) | 2005-03-10 |
US9044473B2 (en) | 2015-06-02 |
WO2005021064A2 (en) | 2005-03-10 |
JP5819574B2 (ja) | 2015-11-24 |
WO2005021064A3 (en) | 2005-08-25 |
EP1673104B2 (en) | 2021-10-27 |
US20150150799A1 (en) | 2015-06-04 |
EP1673104B1 (en) | 2013-10-09 |
EP1673104A4 (en) | 2009-08-12 |
US20090017005A1 (en) | 2009-01-15 |
US11040088B2 (en) | 2021-06-22 |
PL1673104T5 (pl) | 2023-03-06 |
CA2537238C (en) | 2015-01-06 |
AU2004268645A1 (en) | 2005-03-10 |
PL1673104T3 (pl) | 2014-03-31 |
US9089566B2 (en) | 2015-07-28 |
SI1673104T1 (sl) | 2014-02-28 |
US20050048047A1 (en) | 2005-03-03 |
ES2441612T5 (es) | 2022-04-04 |
AU2004268645B2 (en) | 2010-02-18 |
PT1673104E (pt) | 2014-01-15 |
US7442372B2 (en) | 2008-10-28 |
JP2007504166A (ja) | 2007-03-01 |
EP1673104A2 (en) | 2006-06-28 |
SI1673104T2 (sl) | 2022-01-31 |
US20120148558A1 (en) | 2012-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114815T1 (el) | Χορηγηση θεραπευτικων χημικων ενωσεων στον εγκεφαλο και σε αλλους ιστους | |
CY1122128T1 (el) | Θεραπεια ενζυμικης αντικαταστασης με κλιμακωση δοσης για αντιμετωπιση ανεπαρκειας σε οξινη σφιγγομυελιναση | |
AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
CO2019015026A2 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal | |
CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
CY1115617T1 (el) | Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer | |
CO2022002638A2 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla | |
CY1111478T1 (el) | Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
DE602005009176D1 (de) | Behandlung von t-zellen-lymphom mittels 10-propargyl-10-deazaaminopterin | |
AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
EP4289476A3 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
CL2021003280A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
WO2009079452A3 (en) | Treatment and prevention of hiv infection | |
ATE419857T1 (de) | Verwendung von abführmittel zur behandlung des reizdarmsyndroms | |
CL2022002423A1 (es) | Métodos para tratar la enfermedad de fabry | |
NO20073104L (no) | Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser | |
ES2421709T3 (es) | Uso de veneno de abeja para tratar la enfermedad de Parkinson | |
MX2022011278A (es) | Metodo para el tratamiento de afecciones asociadas a covid-19. | |
ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz | |
DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
CN107485791A (zh) | 一种利用积分波微磁场的偏头痛治疗仪 | |
AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
SAHIER et al. | Effect of monochromatic infrared energy light versus laser therapy in diabetic peripheral neuropathy |